In multiple interviews, experts told ICIJ that pharmaceutical companies and policymakers should do more to address the underlying problems that cause counterfeits to flourish in the first place: pricing and availability.
Read more from the #CancerCalculus:
Desperate patients — and even hospitals — have become unwitting customers of fake Keytruda, with potentially fatal consequences.
